Farallon Capital Management LLC Makes New Investment in Abivax SA Sponsored ADR $ABVX

Farallon Capital Management LLC bought a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 805,000 shares of the company’s stock, valued at approximately $68,344,000.

Other institutional investors and hedge funds have also modified their holdings of the company. UBS Group AG increased its stake in shares of Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after acquiring an additional 4,293,606 shares during the last quarter. Darwin Global Management Ltd. acquired a new stake in Abivax during the third quarter valued at $263,698,000. Baker BROS. Advisors LP acquired a new stake in Abivax during the third quarter valued at $74,355,000. Fairmount Funds Management LLC purchased a new position in Abivax in the third quarter valued at about $60,571,000. Finally, Jefferies Financial Group Inc. purchased a new position in Abivax in the third quarter valued at about $38,827,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Oppenheimer set a $131.00 price target on Abivax in a research note on Thursday, January 8th. Morgan Stanley boosted their price target on Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Wedbush started coverage on Abivax in a report on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $142.00 price objective on shares of Abivax in a research report on Tuesday, December 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $134.75.

Abivax Price Performance

NASDAQ ABVX opened at $115.50 on Monday. Abivax SA Sponsored ADR has a fifty-two week low of $4.77 and a fifty-two week high of $148.83. The stock’s 50-day moving average is $118.99 and its two-hundred day moving average is $109.10. The firm has a market cap of $9.13 billion, a P/E ratio of -27.63 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The firm had revenue of ($4.92) million during the quarter. On average, analysts anticipate that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.